Related references
Note: Only part of the references are listed.Impact of68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring
Nina Zhou et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer
Olga Bragina et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Targeting and imaging of HER2 overexpression tumor with a new peptide-based 68Ga-PET radiotracer
Javad Biabani Ardakani et al.
BIOORGANIC CHEMISTRY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Breast cancer
Sibylle Loibl et al.
LANCET (2021)
HER2-targeted therapies - a role beyond breast cancer
Do-Youn Oh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients
Xiaoyi Guo et al.
GASTRIC CANCER (2020)
Evaluation of 99mTc-HYNIC-(ser)3-LTVPWY peptide for glioblastoma imaging
Shima Shahsayari et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2020)
Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours
Pieterjan Debie et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F
Yue Wu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Developing PEGylated Reversed D-Peptide as a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection
Shuaifan Du et al.
BIOCONJUGATE CHEMISTRY (2020)
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT
Gary A. Ulaner et al.
RADIOLOGY (2020)
Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives
Stefania De Luca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6
Emma von Witting et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios
Zhengyuan Zhou et al.
MOLECULAR PHARMACEUTICS (2019)
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Zr-89-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
Gary A. Ulaner et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
Joseph A. O'Donoghue et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Tumor Uptake of Cu-64-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
Joanne E. Mortimer et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation
Zhengyuan Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
An improved 99mTc-HYNIC-(Ser)3-LTVSPWY peptide with EDDA/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor
Fatemeh Khodadust et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo
Siao-Syun Guan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
99mTc-HYNIC-(Ser)3-LTVPWY peptide bearing tricine as co-ligand for targeting and imaging of HER2 overexpression tumor
Nazan Aligholikhamseh et al.
RADIOCHIMICA ACTA (2018)
Molecular Subtypes and Local-Regional Control of Breast Cancer
Simona Maria Fragomeni et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Targeting HER2 in Nuclear Medicine for Imaging and Therapy
Adriana V. F. Massicano et al.
MOLECULAR IMAGING (2018)
89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
Frederike Bensch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab′)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT
Karen Lam et al.
MABS (2017)
New small 99mTc-labeled peptides for HER2 receptor imaging
Hamideh Sabahnoo et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
Dawei Jiang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations
Wedad M. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models
Liqiang Li et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies
Carsten Denkert et al.
LANCET (2017)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
Gary A. Ulaner et al.
CLINICAL NUCLEAR MEDICINE (2017)
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Matthias D'Huyvetter et al.
CLINICAL CANCER RESEARCH (2017)
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee et al.
CLINICAL CANCER RESEARCH (2017)
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
G. Gebhart et al.
ANNALS OF ONCOLOGY (2016)
Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
Gary A. Ulaner et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Development of Companion Diagnostics
David A. Mankoff et al.
SEMINARS IN NUCLEAR MEDICINE (2016)
Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
Hadis Honarvar et al.
THERANOSTICS (2016)
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Jens Sorensen et al.
THERANOSTICS (2016)
Microarray Based Screening of Peptide Nano Probes for HER2 Positive Tumor
Zihua Wang et al.
ANALYTICAL CHEMISTRY (2015)
ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers
Javad Garousi et al.
CANCER RESEARCH (2015)
Peptide therapeutics: current status and future directions
Keld Fosgerau et al.
DRUG DISCOVERY TODAY (2015)
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
Sebastian Trousil et al.
CLINICAL CANCER RESEARCH (2014)
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using Cu-64-DOTA-Trastuzumab PET
Joanne E. Mortimer et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sorensen et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Affinity Maturation of an ERBB2-Targeted SPECT Imaging Peptide by In Vivo Phage Display
Benjamin M. Larimer et al.
MOLECULAR IMAGING AND BIOLOGY (2014)
Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts
Bernadette V. Marquez et al.
MOLECULAR PHARMACEUTICS (2014)
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
Matthias D'Huyvetter et al.
THERANOSTICS (2014)
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer
S. T. Ligthart et al.
ANNALS OF ONCOLOGY (2013)
Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
Matthias Glaser et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer
Catarina Xavier et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Kenji Tamura et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer
Volkan Beylergil et al.
NUCLEAR MEDICINE COMMUNICATIONS (2013)
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
Naoki Niikura et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PET of HER2-Positive Pulmonary Metastases with 18F-ZHER2:342 Affibody in a Murine Model of Breast Cancer: Comparison with 18F-FDG
Gabriela Kramer-Marek et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Lapatinib and 17AAG Reduce 89Zr-Trastuzumab-F(ab')2 Uptake in SKBR3 Tumor Xenografts
Thijs H. Oude Munnink et al.
MOLECULAR PHARMACEUTICS (2012)
Principles of Nuclear Medicine Imaging: Planar, SPECT, PET, Multi-modality, and Autoradiography Systems
Pat Zanzonico
RADIATION RESEARCH (2012)
Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
M. Fani et al.
THERANOSTICS (2012)
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer
Ilse Vaneycken et al.
FASEB JOURNAL (2011)
In Vitro and In Vivo Evaluation of 64Cu-Radiolabeled KCCYSL Peptides for Targeting Epidermal Growth Factor Receptor-2 in Breast Carcinomas
Senthil R. Kumar et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
Richard P. Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Breast Cancer Metastasis: Challenges and Opportunities
J. Lu et al.
CANCER RESEARCH (2009)
Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts
Kristin McLarty et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Eli C. F. Dijkers et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
V. Tolmachev
CURRENT PHARMACEUTICAL DESIGN (2008)
PET versus SPECT: strengths, limitations and challenges
Arman Rahmim et al.
NUCLEAR MEDICINE COMMUNICATIONS (2008)
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
Alfredo Santinelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Evaluation of an 111In-Radiolabeled peptide as a targeting and Imaging agent for ErbB-2 receptor-expressing breast carcinomas
Senthil R. Kumar et al.
CLINICAL CANCER RESEARCH (2007)
Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy
Vladimir Tolmachev et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Patrick J. Perik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
[177Lu]pertuzumab:: experimental studies on targeting of HER-2 positive tumour cells
M Persson et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
PM Smith-Jones et al.
NATURE BIOTECHNOLOGY (2004)
Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells
M Shadidi et al.
FASEB JOURNAL (2002)
Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library
NG Karasseva et al.
JOURNAL OF PROTEIN CHEMISTRY (2002)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Rationally designed anti-HER2/neu peptide mimetic disables p185HER2/neu tyrosine kinases in vitro and in vivo
BW Park et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
